NRGN and Alzheimer disease: Since we saw clear differences in the peptide-to-total full-length Ng ratios between the two AD groups compared to controls and CU-AP for many of the detected peptides, it might be of potential interest to develop an assay capable of measuring these two pools of Ng in the future.